FDA Demands Vision Risk Warning on Ozempic and Mounjaro Labels
FDA requires new warnings on medications like Ozempic and Mounjaro due to a rare risk of vision loss. Understand what has changed on the labels and what the symptoms are.

TL;DR
- The FDA is requiring warnings about Non-arteritic anterior ischemic optic neuropathy (NAION) on Ozempic and Mounjaro labels.
- NAION is a rare eye condition that can cause sudden, painless vision loss due to interrupted blood flow to the optic nerve.
- The FDA's decision is based on clinical trial data showing a slightly higher incidence of NAION in users of these drugs compared to non-users.
- The warning applies to GLP-1 agonists including Ozempic, Wegovy, Mounjaro, and Zepbound.
- Brazil's Anvisa has already mandated similar warnings for semaglutide-based drugs.
- Patients are advised not to stop medication without consulting their doctor, but to seek immediate medical attention for any sudden vision changes.